Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses

Farina, Annarita; Dumonceau, Jean‐Marc; Antinori, Paola; Annessi‐Ramseyer, Isabelle; Frossard, Jean Louis; Hochstrasser, Denis; Delhaye, Myriam; Lescuyer, Pierre

doi:10.1016/j.bbapap.2013.06.010

Cited by 38 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the enumeration of bile EVs stood out as the bestperforming marker of CBD malignant stenoses, allowing the correct diagnosis of all the patients misclassified using serum CA19-9 (n ¼ 8) and bile CEAM6 (n ¼ 3), which has been described as one of the most promising biomarkers in bile. [22][23][24] Of note, in our verification cohort, CEAM6 confirmed its higher diagnostic accuracy compared with serum CA19-9 ( Table 2).…”

Section: Diagnostic Performance Of Bile and Serum Ev Concentration (Vsupporting

confidence: 63%

“…These features suggest that EV enumeration in bile using NTA is an extremely promising candidate for clinical implementation once our findings have been confirmed by independent researchers. In comparison, dosing alternative highly performant protein biomarkers in bile (eg, CEAM6) [22][23][24] is difficult to automate, with a consequent increase of costs and delays.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Diagnostic Performance Of Bile and Serum Ev Concentration (Vsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…One approach to overcome this problem is to analyse more proximal biofluids such as saliva, urine, exhaled breath condensate and bronchoalveolar lavage fluid (BALF) [24], [25], [26], [27], [28]. Proximal biofluids have a much reduced dynamic range of protein abundances and in some cases are in direct contact with the site of the disease [29].…”

Section: Introductionmentioning

confidence: 99%

Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry

et al. 2017

View full text Add to dashboard Cite

BackgroundLung cancer is the leading cause of cancer-related mortality in both men and women throughout the world. The need to detect lung cancer at an early, potentially curable stage, is essential and may reduce mortality by 20%. The aim of this study was to identify distinct proteomic profiles in bronchoalveolar fluid (BALF) and plasma that are able to discriminate individuals with benign disease from those with non-small cell lung cancer (NSCLC).MethodsUsing label-free mass spectrometry analysis of BALF during discovery-phase analysis, a significant number of proteins were found to have different abundance levels when comparing control to adenocarcinoma (AD) or squamous cell lung carcinoma (SqCC). Validation of candidate biomarkers identified in BALF was performed in a larger cohort of plasma samples by detection with enzyme-linked immunoassay.ResultsFour proteins (Cystatin-C, TIMP-1, Lipocalin-2 and HSP70/HSPA1A) were selected as a representative group from discovery phase mass spectrometry BALF analysis. Plasma levels of TIMP-1, Lipocalin-2 and Cystatin-C were found to be significantly elevated in AD and SqCC compared to control.ConclusionThe results presented in this study indicate that BALF is an important proximal biofluid for the discovery and identification of candidate lung cancer biomarkers.General significanceThere is good correlation between the trend of protein abundance levels in BALF and that of plasma which validates this approach to develop a blood biomarker to aid lung cancer diagnosis, particularly in the era of lung cancer screening. The protein signatures identified also provide insight into the molecular mechanisms associated with lung malignancy.

show abstract

“…Of note, Lewis antigen–negative patients do not produce CA 19‐9. The search for more sensitive and specific CCA biomarkers is ongoing, and analysis of bile for tumor antigens such as carcinoembryonic cell adhesion molecule 6 might be a promising new approach …”

Section: Diagnostic Approachmentioning

confidence: 99%